logo.jpg
Genmab Announces Financial Results for the First Quarter of 2014
May 07, 2014 11:00 ET | Genmab A/S
May 7, 2014; Copenhagen, Denmark; Interim Report First Quarter 2014 Arzerra® (ofatumumab) was approved by the FDA in combination with chlorambucil for previously untreated patients with...
logo.jpg
Genmab Announces New Phase III Study of Daratumumab in Multiple Myeloma & Improves 2014 Financial Guidance
May 01, 2014 14:58 ET | Genmab A/S
Company Announcement Second Phase III study of daratumumab in multiple myeloma Patient recruitment to start in the coming months 2014 guidance improved due to anticipated...
logo.jpg
Genmab offentliggør nyt fase III studie med daratumumab til behandling af myelomatose og opjusterer forventningerne til 2014
May 01, 2014 14:58 ET | Genmab A/S
Selskabsmeddelelse Andet fase III studie med daratumumab til behandling af myelomatose Rekruttering af patienter indledes i de kommende måneder Forventningerne til 2014 opjusteres som...
logo.jpg
First Quarter 2014 Net Sales Figures for Arzerra
April 30, 2014 07:02 ET | Genmab A/S
Company Announcement Worldwide net sales of Arzerra® (ofatumumab) in Q1 2014 totaled GBP 15.6 million Genmab expects royalty payment of approximately DKK 28 million Copenhagen, Denmark;...
logo.jpg
Nettoomsætning for Arzerra i første kvartal 2014
April 30, 2014 07:02 ET | Genmab A/S
Selskabsmeddelelse   Den globale nettoomsætning for Arzerra® (ofatumumab) i første kvartal 2014 udgjorde GBP 15,6 mio. Genmab forventer royaltybetaling på ca. DKK 28...
logo.jpg
GSK and Genmab Receive FDA Approval for Arzerra® (ofatumumab) as First-Line Treatment in Combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia (CLL) for Whom Fludarabine-Based Therapy is Considered Inappropriate
April 17, 2014 15:34 ET | Genmab A/S
Company Announcement Arzerra now approved for use in previously untreated patients for whom fludarabine-based therapy is considered inappropriate Approval based on Phase III data from study...
logo.jpg
GSK og Genmab opnår godkendelse fra FDA for Arzerra® (ofatumumab) som førstelinjebehandling i kombination med chlorambucil til behandling af patienter med kronisk lymfatisk leukæmi (CLL) for hvilke fludarabin-baseret behandling ikke anses f
April 17, 2014 15:34 ET | Genmab A/S
Selskabsmeddelelse Arzerra nu godkendt til behandling af tidligere ubehandlede patienter, for hvilke fludarabin-baseret behandling ikke anses for egnet Godkendelsen er baseret på resultater...
logo.jpg
Articles of Association for Genmab A/S
April 15, 2014 11:16 ET | Genmab A/S
Genmab A/S has published its Articles of Association dated April 9, 2014. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm Contact: Rachel...
logo.jpg
Selskabsvedtægter for Genmab A/S
April 15, 2014 11:16 ET | Genmab A/S
Selskabsvedtægter for Genmab A/S dateret den 9. april 2014 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
logo.jpg
Constitution of the Board of Directors in Genmab A/S and Grant of Warrants to Employees
April 09, 2014 12:55 ET | Genmab A/S
Company Announcement Copenhagen, Denmark; April 9, 2014 – Following Genmab A/S’ (OMX: GEN) Annual General Meeting held on April 9, 2014, the Company’s Board of Directors met to constitute itself...